List of largest biomedical companies by revenue

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

The following is a list of the top independent pharmaceutical, biotechnology and medical companies ranked by their revenue generated in (billion dollars) in the respective financial year, it does not include biotechnology companies that are now owned by, or part of, larger pharmaceutical groups.

The change is the companies relative position in this list, compared to their relative position in the prior year; i.e., an increase would be moving closer to rank 1 and vice versa. Green cells indicate years where revenue increased compared to the previous year, red cells indicate those years where there has been a decrease.

Top pharmaceutical companies with revenue in $ billion[edit]

Rank Chg Company 2020
USD billions
2019
USD billions
2018
USD billions
2017
USD billions
2016
USD billions
2015
USD billions
2014
USD billions
2013
USD billions
2012
USD billions
2011
USD billions
1 Steady United States Johnson & Johnson
NYSEJNJ
60.11 Q3[1] 82.06[2] 81.60[3] 76.50[4] 71.89[5] 70.10[6] 74.30[7] 71.31[8] 67.20[9] 65.00[10]
2 Steady Switzerland Roche
SIXROG
47.93 Q3[11] 63.85[12] 56.86[13] 57.37[14] 50.11[15] 47.70[16] 49.86[17] 48.53[18] 47.80[19] 45.21[20]
3 Decrease 1 United States Pfizer
NYSEPFE
35.96 Q3[21] 51.75[22] 53.60[23] 52.54[24] 52.82[25] 48.85[26] 49.61[27] 51.58[28] 58.99[29] 65.26[30]
4 Increase 1 China Sinopharm
SEHK1099
31.08 Q2[31] 60.18[32] 48.75[33] 43.63[34] 36.56[35] 32.36[36] 28.32[37] 23.61[38] 19.31[39] 14.46[40]
5 Steady Germany Bayer
FWBBAYN
37.32 Q3[41] 48.02 [42] 45.06[43] 37.94[44] 25.27[45] 24.09[46] 25.47[47] 24.17[48] 24.30[49] 23.11[50]
6 Steady Switzerland Novartis
NYSENVS
35.89 Q3[51] 47.45[52] 44.75[53] 49.11[54] 48.52[55] 49.41[56] 58.00[57] 57.36[58] 56.67[59] 58.57[60]
7 Increase 1 United States Merck & Co.
NYSEMRK
35.48 Q3[61] 46.84[62] 42.30[63] 40.10[64] 39.80[65] 39.50[66] 42.24[67] 44.03[68] 47.27[69] 48.05[70]
8 Decrease 1 United Kingdom GlaxoSmithKline
LSEGSK
32.83 Q3[71] 43.92[72] 43.14[73] 42.05[74] 34.79[75] 29.84[76] 37.96[77] 41.61[78] 39.93[79] 41.39[80]
9 Steady France Sanofi
NYSESNY
31.13 Q3[81] 39.28[82] 39.07[83] 42.91[84] 36.57[85] 36.73[86] 43.07[87] 42.08[88] 46.41[89] 44.34[90]
10 Steady United States AbbVie
NYSEABBV
31.93 Q3[91] 33.27[92] 32.75[93] 28.22[94] 25.56[95] 22.82[96] 19.96[97] 18.79[98]
11 Steady United States Abbott Laboratories
NASDAQABT
15.05 Q2[99] 31.90[100] 30.60[101] 27.39[102] 20.85[103] 20.41[104] 20.25[105] 21.85[106] 39.87[107] 38.85[108]
12 Steady United States Medtronic
NYSEMDT
15.02 Q2[109] 31.2[110] 30.4[111] 29.29[112] 27.6[113] 24.4[114] 20.25[115] 23.85[116] 22.7[117] 18.62[118]
13 Increase 8 Japan Takeda Pharmaceutical
TYO: 4502
15.20 Q2[119] 31.17[120] 19.10[121] 16.70[122] 15.96[123] 14.93 16.84 17.36 18.91 17.80
14 Increase 1 United States Bristol-Myers Squibb
NASDAQBMY
31.45 Q3 [124] 26.15[125] 22.56[126] 20.80[127] 19.43[128] 16.56[129] 15.88[130] 16.39[131] 17.62[132] 21.24[133]
15 Decrease 2 United States Thermo Fisher Scientific
NYSETMO
21.67 Q3[134] 25.54[135] 24.36[135] 20.92[136] 18.27[137] 16.97[138] 16.89[139] 13.09[139] 12.51[140] 11.56[140]
16 Increase 1 United Kingdom/Sweden AstraZeneca
LSEAZN
19.21 Q3[141] 24.38[142] 22.09[143] 22.47[144] 23.00[145] 24.71[146] 26.10[147] 25.71[148] 27.97[149] 33.59[150]
17 Decrease 3 United States Amgen
NASDAQAMGN
18.79 Q3[151] 23.40[152] 23.70[153] 22.80[154] 22.99[155] 21.66[156] 20.06[157] 18.68[158] 17.30[159] 15.58[160]
18 Decrease 2 United States Gilead Sciences
NASDAQGILD
17.27 Q3[161] 22.45[162] 22.13[163] 25.70[164] 30.39[164] 32.15[164] 24.47[164] 10.80[164] 9.70[164] 8.39[164]
19 Decrease 1 United States Eli Lilly & Co
NYSELLY
17.10 Q3[165] 22.32[166] 21.49[167] 22.90[168] 21.22[169] 20.00[170] 19.62[171] 23.11[172] 22.60[173] 24.29[174]
20 Increase 1 United States GE Healthcare
Subsidiary of General Electric
11.12 Q3[175] 19.94[176] 19.78[177] 19.02[178] 18.21[179] 17.64[180] 18.30[181] 18.20[182] 18.29[183]
21 Decrease 2 United States Viatris
NASDAQVTRS
20.4
22 Decrease 2 Germany Boehringer Ingelheim
Private
19.48[184] 21.67[185] 17.54[186] 16.41[186] 17.70[186] 18.68[186] 18.89[186] 18.34[186]
23 Increase 2 Denmark Novo Nordisk
NYSENVO
15.11 Q3[187] 18.30[188] 16.99[189] 18.77[190] 16.61[191] 16.06[192] 15.83[193] 14.88[194] 13.48[195] 11.56[196]
24 Increase 2 Germany Merck Group
ETR: MRK
15.36 Q3[197] 18.25[198] 16.48[199] 18.70[200] 16.62[201] 14.25[202] 15.29[203] 14.73[200] 14.36[200] 14.31[200]
25 Decrease 3 United States Danaher Corporation
NYSEDHR
4.34 Q1[204] 17.91[205] 19.89[206] 18.33[207] 16.88[208] 20.56[209] 19.91[210] 19.12[211] 18.26[212] 16.09[213]
26 Decrease 3 United States Becton, Dickinson and Company
NYSEBDX
7.34 Q1[214] 17.45[215] 13.89[216] 15.33[217] 16.88[218] 12.56[219] 14.2[220] 13.5[221] 11.26[222] 10.08[223]
27 Decrease 2 Israel/United States Teva Pharmaceutical Industries
NASDAQTEVA
12.21 Q3[224] 16.89[225] 18.90[226] 22.40[227] 21.90[228] 20.00[229] 20.27[230] 20.31[231] 18.31[232] 16.12[233]
28 Steady Germany Siemens Healthineers
FWBSHL
10.58 Q3[234][235] 16.29[236] 15.44[237] 16.56[238] 14.25[239] 14.06[240]
29 Steady United States Stryker Corporation
NYSESYK
6.35 Q2[241] 14.90[242] 13.60[243] 12.44[243] 11.33[244] 9.95[244] 9.68[245] 9.02[245] 8.66[246] 8.31[246]
30 Steady United States Biogen
NASDAQBIIB
10.59 Q3[247] 14.38[248] 13.45[249] 12.30[250] 11.40[251] 10.80[252] 9.70[253] 6.90[254] 5.50[255] 5.00[256]
31 Steady Japan Astellas Pharma
TYO: 4503
12.20[257] 12.27[258] 12.07 12.63 11.48 10.49 9.25 8.92 8.78
32 Increase 1 United States Labcorp
NYSELH
5.59 Q2[259] 11.55[260] 11.33[261] 10.31[261] 9.55[261] 8.51[261] 6.01[261] 5.81[262] 5.67[262] 5.54[262]
33 Steady United States Baxter International
NYSEBAX
5.50 Q2[263] 11.36[264] 11.13 [265] 10.56 [265] 10.16 [266] 9.97 [267] 10.72 [268] 14.97 [269] 14.19 [270] 13.89 [270]
34 Steady United States IQVIA
NYSEIQV
8.06 Q3 [271] 11.09 [272] 10.41 [273] 9.70 [274] 5.36 [275] 4.33 [276] 4.17 [277] 3.81 [278] 3.69 [279]
35 Steady United States Boston Scientific
NYSEBSX
10.65[280] 9.82[280] 9.05[281] 9.08[282] 8.07[283] 7.46[284] 7.14[285] 7.25[286] 7.62[287]
36 Steady United States Quest Diagnostics
NYSEDGX
7.60[280] 6.5[280] 5.05[288] 6.08[289] 8.07[290] 3.46[291] 4.14[292] 7.25[293] 7.62[294]
37 Increase 2 United States Alcon
NYSEALC
7.2

See also[edit]

Notes[edit]

References[edit]

  1. ^ https://johnsonandjohnson.gcs-web.com/static-files/d2b730a1-483a-4f43-ba8c-3134416a3e7c
  2. ^ "Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results: | BioSpace".
  3. ^ "Johnson & Johnson Reports 2018 Fourth-Quarter Results:". Content Lab - U.S.
  4. ^ "Johnson & Johnson Reports 2017 Fourth-Quarter Results: - Johnson & Johnson". www.jnj.com.
  5. ^ "Johnson & Johnson Reports 2016 Fourth-Quarter Results - Johnson & Johnson". www.jnj.com.
  6. ^ "Johnson & Johnson Reports 2015 Fourth-Quarter Results:". Archived from the original on 2016-02-11. Retrieved 2018-01-28.
  7. ^ "Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com.
  8. ^ "Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com.
  9. ^ "Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:".
  10. ^ "Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:".
  11. ^ https://www.roche.com/dam/jcr:8c017df4-4f19-4b84-ad1a-ac0328a30d4f/en/irp201015-a.pdf
  12. ^ https://www.roche.com/dam/jcr:e49f6995-e813-43c1-9302-c9b7d0bddbc8/en/irp200130-a.pdf
  13. ^ https://www.roche.com/dam/jcr:af865dfd-50fb-458b-9cac-34097db9d3ec/en/ar18e.pdf
  14. ^ "Roche reports good results in 2017". www.roche.com.
  15. ^ https://www.roche.com/dam/jcr:ee2f197f-5487-4629-9e28-66b77c9cbbab/en/ar16e.pdf
  16. ^ https://www.roche.com/dam/jcr:9b36e11d-495c-42f5-b757-e80c4e88d793/en/gb15e.pdf
  17. ^ https://www.roche.com/dam/jcr:880b44a1-3fd6-4e66-bf10-f4af1e724d4d/en/gb14e.pdf
  18. ^ https://www.roche.com/dam/jcr:64fd6b2d-1a76-467f-badd-ab94b85b6d70/en/gb13e.pdf
  19. ^ https://www.roche.com/dam/jcr:3e048249-e3ce-4969-a77e-cc90d8f3fa73/en/gb12e.pdf
  20. ^ https://www.roche.com/dam/jcr:52174b39-feab-4210-82f6-9b8786a69ecf/en/gb11e.pdf
  21. ^ https://s21.q4cdn.com/317678438/files/doc_financials/2020/q3/Q3-2020-PFE-Earnings-Release.pdf
  22. ^ "PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS | BioSpace".
  23. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2018/q4/Q4-2018-PFE-Earnings-Release.pdf
  24. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2017/Q4_2017_PFE_Earnings_Release.pdf
  25. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2016/2016-financial-report.pdf
  26. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2015/2015_Pfizer_Financial_Report.pdf
  27. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2014/2014_Pfizer_Financial_Report.pdf
  28. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2013/FinancialReport2013.pdf
  29. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2012/financial2012.pdf
  30. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2011/financial2011.pdf
  31. ^ http://ir.sinopharmgroup.com.cn/attachment/2020091708240127219443832_en.pdf
  32. ^ http://ir.sinopharmgroup.com.cn/attachment/202004240816014279248723_en.pdf
  33. ^ http://ir.sinopharmgroup.com.cn/attachment/2019042506350100033473013_en.pdf
  34. ^ http://ir.sinopharmgroup.com.cn/attachment/2018042506320200033121116_en.pdf
  35. ^ http://ir.sinopharmgroup.com.cn/attachment/2017042106200200012785604_en.pdf
  36. ^ http://ir.sinopharmgroup.com.cn/attachment/201607131609541765679138_en.PDF
  37. ^ http://ir.sinopharmgroup.com.cn/attachment/2015041006320100032166702_en.pdf
  38. ^ http://ir.sinopharmgroup.com.cn/attachment/20140410061701001886801_en.pdf
  39. ^ http://ir.sinopharmgroup.com.cn/attachment/20130419164701001633683_en.pdf
  40. ^ http://ir.sinopharmgroup.com.cn/attachment/20120420064701001411060_en.pdf
  41. ^ https://www.bayer.com/sites/default/files/bayer-ag-quarterly-statement-q3-2020.pdf
  42. ^ "Bayer AG Annual Report 2019". www.bayer.com.
  43. ^ "Bayer's Annual Report 2018". www.annualreport2018.bayer.com.
  44. ^ http://www.annualreport2017.bayer.com/servicepages/downloads/files/bayer_ar17_entire.pdf
  45. ^ http://www.annualreport2016.bayer.com/servicepages/downloads/files/bayer_ar16_entire.pdf
  46. ^ http://www.annualreport2015.bayer.com/servicepages/downloads/files/entire_bayer_ar15.pdf
  47. ^ AG, Bayer. "Bayer – Global Home". www.bayer.com.
  48. ^ https://www.bayer.com/en/ar-2013.pdfx
  49. ^ https://www.bayer.com/en/ar-2012.pdfx
  50. ^ https://www.bayer.com/en/ar-2011.pdfx
  51. ^ https://www.novartis.com/sites/www.novartis.com/files/q3-2020-media-release-en.pdf
  52. ^ https://www.novartis.com/sites/www.novartis.com/files/q4-2019-media-release-en.pdf
  53. ^ https://www.novartis.com/sites/www.novartis.com/files/q4-2018-media-release-en.pdf
  54. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2018-01-29. Retrieved 2018-01-28.CS1 maint: archived copy as title (link)
  55. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2016-en.pdf
  56. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2015-en.pdf
  57. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2014-en.pdf
  58. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2013-en.pdf
  59. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2012-en.pdf
  60. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2011-en.pdf
  61. ^ https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/
  62. ^ https://www.biospace.com/article/releases/merck-announces-fourth-quarter-and-full-year-2019-financial-results/?s=72
  63. ^ "Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results". BioSpace.
  64. ^ LaVito, Angelica (2 February 2018). "Merck posts mixed fourth-quarter results as Keytruda sales skyrocket".
  65. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2017/Q4/merck-q4-10k.pdf
  66. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2015/annual/MRK_2015_Form_10-K_FINAL_r879.pdf
  67. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2014/annual/2014-Form-10-K_FINAL_022715.pdf
  68. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2013/annual/MRK_2013_Form_10_K_FINAL_022714.pdf
  69. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2012/annual/MRK_form_10_k_2012.pdf
  70. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2011/annual/form-10-k-2011.pdf
  71. ^ https://www.gsk.com/media/6189/q3-2020-results-announcement.pdf
  72. ^ https://www.gsk.com/media/5820/fy-2019-results-announcement.pdf
  73. ^ "GSK delivers sales, earnings and cash flow growth in 2018 - GSK". www.gsk.com.
  74. ^ https://www.gsk.com/media/4629/fy-2017-results-announcement.pdf
  75. ^ https://www.gsk.com/media/3609/annual-report-2016.pdf
  76. ^ https://www.gsk.com/media/2718/gsk-annual-report-2016.pdf
  77. ^ https://www.gsk.com/media/2710/gsk-annual-report-2014-interactive.pdf
  78. ^ https://www.gsk.com/media/2701/annual-report-2013-interactive.pdf
  79. ^ https://www.gsk.com/media/2694/annual-report-2012.pdf
  80. ^ https://www.gsk.com/media/2696/annual-report-2011.pdf
  81. ^ https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/2020_10_29_Q3_Results_PR_EN.pdf?la=en&hash=8FAFC6A6DB6E045241FE3E1DEF5410C1
  82. ^ https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2019
  83. ^ https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/press-releases/Q42018results.pdf?la=en&hash=CDCE30350F0C658C000A909535AD9AF636A93560
  84. ^ https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/en/investors/docs/press-releases/Press_release_Q4_FY_2017.pdf
  85. ^ https://en.sanofi.com/Images/49288_20-F_2016.pdf
  86. ^ https://en.sanofi.com/Images/45889_Sanofi_20-F_2015_V2.pdf
  87. ^ https://en.sanofi.com/Images/38473_Sanofi_20-F_2014.pdf
  88. ^ https://en.sanofi.com/Images/35795_20F_SANOFI_2013.pdf
  89. ^ https://en.sanofi.com/Images/31972_20-F_2012_V2.pdf
  90. ^ https://en.sanofi.com/Images/29804_20F_2011.pdf
  91. ^ https://investors.abbvie.com/static-files/ee4ada89-b004-4b3b-a697-cdc9abe0844c
  92. ^ https://www.biospace.com/article/releases/abbvie-reports-full-year-and-fourth-quarter-2019-financial-results/?s=72
  93. ^ "AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results - AbbVie News Center". news.abbvie.com.
  94. ^ "Financial Release - AbbVie". investors.abbvie.com.
  95. ^ "Financial Release - AbbVie". investors.abbvie.com.
  96. ^ "Financial Release - AbbVie". investors.abbvie.com.
  97. ^ "Financial Release - AbbVie". investors.abbvie.com.
  98. ^ "Financial Release - AbbVie". investors.abbvie.com.
  99. ^ https://www.abbottinvestor.com/node/32476/html#StatementofEarnings_149166
  100. ^ https://www.biospace.com/article/releases/abbott-reports-fourth-quarter-2019-results-announces-strong-forecast-for-2020/?s=72
  101. ^ "Abbott Reports 2018 Results and Issues Strong Forecast for 2019". BioSpace.
  102. ^ Abbott. "Abbott Reports Fourth-Quarter 2017 Results". www.prnewswire.com.
  103. ^ Abbott. "Abbott Reports Fourth-Quarter 2016 Results". www.prnewswire.com.
  104. ^ "Abbott Reports Fourth-Quarter 2015 Results".
  105. ^ "Abbott Reports Fourth-Quarter 2014 Results".
  106. ^ Abbott. "Abbott Reports Fourth-Quarter and Full-Year 2013 Results". www.prnewswire.com.
  107. ^ "Abbott Reports Fourth-Quarter and Full-Year 2012 Results".
  108. ^ "Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2011 Earnings - FiercePharma". www.fiercepharma.com.
  109. ^ https://www.abbottinvestor.com/node/32476/html#StatementofEarnings_149166
  110. ^ https://www.biospace.com/article/releases/abbott-reports-fourth-quarter-2019-results-announces-strong-forecast-for-2020/?s=72
  111. ^ "Abbott Reports 2018 Results and Issues Strong Forecast for 2019". BioSpace.
  112. ^ Abbott. "Abbott Reports Fourth-Quarter 2017 Results". www.prnewswire.com.
  113. ^ Abbott. "Abbott Reports Fourth-Quarter 2016 Results". www.prnewswire.com.
  114. ^ "Abbott Reports Fourth-Quarter 2015 Results".
  115. ^ "Abbott Reports Fourth-Quarter 2014 Results".
  116. ^ Abbott. "Abbott Reports Fourth-Quarter and Full-Year 2013 Results". www.prnewswire.com.
  117. ^ "Abbott Reports Fourth-Quarter and Full-Year 2012 Results".
  118. ^ "Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2011 Earnings - FiercePharma". www.fiercepharma.com.
  119. ^ https://www.takeda.com/4ab331/siteassets/system/investors/quarterly-announcements/fy2020/qr2020_q2_qfr_en.pdf
  120. ^ https://www.takeda.com/newsroom/newsreleases/2020/takeda-accelerates-transformation-solid-fy2019-results-confidence-in-fy2020-growth-momentum/
  121. ^ https://www.takeda.com/newsroom/newsreleases/2019/takeda-reports-fy2018-full-year-results-and-issues-fy2019-guidance/
  122. ^ "Takeda reports FY2017 full year results and issues FY2018 guidance". www.takeda.com.
  123. ^ "Takeda Pharmaceutical Company Limited and its Subsidiaries Consolidated Financial Statements Under IFRSs and Independent Auditor's Report" (PDF).
  124. ^ https://s21.q4cdn.com/104148044/files/doc_financials/quarterly_reports/2020/BMY-Q32020-Earnings-Press-Release.pdf
  125. ^ https://www.biospace.com/article/releases/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2019/?s=79
  126. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results - BMS Newsroom". news.bms.com.
  127. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results". investors.bms.com.
  128. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results - BMS Newsroom". news.bms.com.
  129. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results - BMS Newsroom". news.bms.com.
  130. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results - BMS Newsroom". news.bms.com.
  131. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results - BMS Newsroom". news.bms.com.
  132. ^ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/Bristol-Myers-Squibb-2012AR-lr.pdf
  133. ^ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/BristolMyersSquibb-2011-AnnualReport.pdf
  134. ^ https://s1.q4cdn.com/008680097/files/doc_financials/2020/q3/Q3'20-10Q.pdf
  135. ^ a b https://www.biospace.com/article/releases/thermo-fisher-scientific-reports-fourth-quarter-and-full-year-2019-results/?s=72
  136. ^ https://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2018/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2017-Results/default.aspx
  137. ^ https://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2017/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2016-Results/default.aspx
  138. ^ https://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2016/Thermo-Fisher-Scientific-Reports-Record-Fourth-Quarter-and-Full-Year-2015-Results/default.aspx
  139. ^ a b https://ir.thermofisher.com/investors/news-and-events/news-releases/news-release-details/2015/Thermo-Fisher-Scientific-Reports-Strong-Fourth-Quarter-and-Full-Year-2014-Results/default.aspx
  140. ^ a b http://thermofisher.mediaroom.com/2013-01-31-Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2012-Results
  141. ^ https://www.astrazeneca.com/content/dam/az/PDF/2020/q3/Year-to-date_and_Q3_2020_results_announcement.pdf
  142. ^ https://www.astrazeneca.com/content/dam/az/PDF/2019/full-year/Full-year_and_Q4_2019_results_announcement.pdf
  143. ^ https://www.astrazeneca.com/content/dam/az/PDF/2018/full-year/Full-Year_2018_Results_announcement.pdf
  144. ^ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf
  145. ^ https://www.astrazeneca.com/content/dam/az/PDF/Full_year_and_q4_2016_results/Full_Year_and_Q4_2016_Results_announcement.pdf
  146. ^ "Full-Year and Q4 2015 Results". www.astrazeneca.com.
  147. ^ "AstraZeneca PLC fourth quarter and full year results 2014". www.astrazeneca.com.
  148. ^ "AstraZeneca PLC fourth quarter and full year results 2013 - AstraZeneca". www.astrazeneca.com.
  149. ^ "AstraZeneca PLC Fourth quarter and full year results 2012". www.astrazeneca.com.
  150. ^ "AstraZeneca PLC Fourth quarter and full year results 2011". www.astrazeneca.com.
  151. ^ https://www.amgen.com/media/news-releases/2020/10/amgen-reports-third-quarter-2020-financial-results/
  152. ^ https://www.biospace.com/article/releases/amgen-reports-fourth-quarter-and-full-year-2019-financial-results/?s=72
  153. ^ "Amgen - Investors - Press Release". investors.amgen.com.
  154. ^ "Amgen Reports Fourth Quarter And Full Year 2017 Financial Results". www.amgen.com.
  155. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY1NTQ1fENoaWxkSUQ9MzczMzk1fFR5cGU9MQ==&t=1
  156. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjI2OTYzfENoaWxkSUQ9MzI5ODc3fFR5cGU9MQ==&t=1
  157. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTc0NTMzfENoaWxkSUQ9Mjc3NjczfFR5cGU9MQ==&t=1
  158. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM3Nzc3fENoaWxkSUQ9MjI2ODE2fFR5cGU9MQ==&t=1
  159. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDk5NjQxfENoaWxkSUQ9NTM5NDU4fFR5cGU9MQ==&t=1
  160. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTM0MzEzfENoaWxkSUQ9LTF8VHlwZT0z&t=1
  161. ^ http://investors.gilead.com/static-files/aff01ff7-e399-4a73-9b64-f3ad421253da
  162. ^ https://www.biospace.com/article/releases/gilead-sciences-announces-fourth-quarter-and-full-year-2019-financial-results/?s=72
  163. ^ "Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results". BioSpace.
  164. ^ a b c d e f g "Investor Overview". Gilead Sciences.
  165. ^ https://investor.lilly.com/static-files/e84b2d25-8e5b-4041-b7f0-8a1749fb9f77
  166. ^ https://www.biospace.com/article/releases/lilly-reports-strong-fourth-quarter-and-full-year-2019-financial-results-updates-2020-guidance-for-pending-dermira-acquisition/?s=72
  167. ^ "Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology". BioSpace.
  168. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x970018/15B962F7-AF5A-4FFA-BE13-42206D3A0820/Q4_2017_PressRelease.pdf
  169. ^ "Lilly Reports Fourth-Quarter and Full-Year 2016 Results (NYSE:LLY)". investor.lilly.com.
  170. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x871993/5BE670A3-2B82-4876-8471-CA6BC3BD49F8/Lilly_Q4_2015_Press_Release.pdf
  171. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x806120/8637C572-31C4-402E-A179-5E107A5366B2/Q414_Lilly_Sales_and_Earnings_Press_Release.pdf
  172. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x721860/2DB60538-94FE-4E96-98D2-DA72CC301EA0/Q413%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
  173. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x631117/85679233-E13C-4FE7-9431-E97EFFDA6D5D/Q412%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
  174. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x538046/24A15621-7850-45EC-8E20-30535C3D9FC9/Q411_Lilly_Sales_and_Earnings_Press_Release.pdf
  175. ^ https://www.ge.com/sites/default/files/ge_webcast_presentation_10282020.pdf
  176. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  177. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  178. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  179. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  180. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  181. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  182. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  183. ^ https://www.statista.com/statistics/277734/revenue-for-general-electric-healthcare-segment-since-2008/
  184. ^ http://annualreport.boehringer-ingelheim.com/fileadmin/Download-Center/BI_GB_18_en_ohne_Unterschriften.pdf
  185. ^ "Boehringer Ingelheim 2017 Annual Report" (PDF). www.boehringer-ingelheim.com.
  186. ^ a b c d e f "Boehringer Ingelheim total revenue 2007-2017 - Statistic". Statista.
  187. ^ https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/quarterly_financial_reports/2020/20201030_Q3-CA.pdf
  188. ^ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2020/20200502_Financial%20statement%20Q4%202019_UK.pdf
  189. ^ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2019/20190201_Financial%20statement%20Q4%202018_UK.pdf
  190. ^ "News details". www.novonordisk.com.
  191. ^ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2017/20170202_Financial%20statement_FY%202016_UK.pdf
  192. ^ Transcripts, SA (3 February 2016). "Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q4 2015 Results - Earnings Call Transcript".
  193. ^ Transcripts, SA (30 January 2015). "Novo Nordisk's (NVO) CEO Lars Sorensen on Q4 2014 Results - Earnings Call Transcript".
  194. ^ Transcripts, SA (31 January 2014). "Novo Nordisk A/S Management Discusses Q4 2013 Results - Earnings Call Transcript".
  195. ^ Transcripts, SA (31 January 2013). "Novo Nordisk's CEO Discusses Q4 2012 Results - Earnings Call Transcript".
  196. ^ http://www.novonordisk.co.uk/content/dam/Denmark/HQ/Commons/documents/Novo-Nordisk-AR-2011-en.pdf
  197. ^ https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2020-q3/en/2020-Q3-Financial-Statement-EN.pdf
  198. ^ https://www.merckgroup.com/investors/reports-and-financials/earnings-materials/2019-q4/en/2019-Q4-Report-EN.pdf
  199. ^ "Q4/FY Results of 2018 - News - Merck KGaA, Darmstadt, Germany". www.emdgroup.com.
  200. ^ a b c d "404 page - EMD Group". www.emdgroup.com.
  201. ^ http://ar2016.merckgroup.com/sites/default/files/downloads/en/merck_annual_report_2016.pdf
  202. ^ http://ar2015.emdgroup.com/sites/default/files/downloads/emd/Merck_GB2015_EN.pdf
  203. ^ http://ar2014.merckgroup.com/sites/default/files/downloads/en/Merck_GB2014_EN.pdf
  204. ^ http://investors.danaher.com/image/1Q2020+Danaher+Earnings+Presentation.pdf
  205. ^ http://investors.danaher.com/image/4Q2019+Danaher+Earnings+Presentation.pdf
  206. ^ http://investors.danaher.com/download/Danaher_Annual_Report_2018.pdf
  207. ^ http://investors.danaher.com/download/danaher_2017_annualreport.pdf
  208. ^ http://investors.danaher.com/download/Danaher_2016+Annual+Report.pdf
  209. ^ http://investors.danaher.com/download/2015+Danaher+Annual+Report.pdf
  210. ^ http://investors.danaher.com/download/DHR_AR_2014.pdf
  211. ^ http://investors.danaher.com/download/DHR_AR_2013.pdf
  212. ^ http://investors.danaher.com/download/DHR_AR_2012.pdf
  213. ^ http://investors.danaher.com/download/DHR_AR_2011.pdf
  214. ^ http://investors.danaher.com/image/1Q2020+Danaher+Earnings+Presentation.pdf
  215. ^ http://investors.danaher.com/image/4Q2019+Danaher+Earnings+Presentation.pdf
  216. ^ http://investors.danaher.com/download/Danaher_Annual_Report_2018.pdf
  217. ^ http://investors.danaher.com/download/danaher_2017_annualreport.pdf
  218. ^ http://investors.danaher.com/download/Danaher_2016+Annual+Report.pdf
  219. ^ http://investors.danaher.com/download/2015+Danaher+Annual+Report.pdf
  220. ^ http://investors.danaher.com/download/DHR_AR_2014.pdf
  221. ^ http://investors.danaher.com/download/DHR_AR_2013.pdf
  222. ^ http://investors.danaher.com/download/DHR_AR_2012.pdf
  223. ^ http://investors.danaher.com/download/DHR_AR_2011.pdf
  224. ^ https://s24.q4cdn.com/720828402/files/doc_financials/2020/q3/Q3-2020-Form-10-Q.pdf
  225. ^ https://www.biospace.com/article/releases/teva-reports-fourth-quarter-and-full-year-2019-financial-results/?s=72
  226. ^ https://s24.q4cdn.com/720828402/files/doc_downloads/doc_financial/2018/q4/Teva-Form-10-K-2018.pdf
  227. ^ "Teva Reports 2017 Full Year and Fourth Quarter Financial Results".
  228. ^ http://www.tevapharm.com/news/teva_reports_full_year_and_fourth_quarter_2016_financial_results_02_17.aspx
  229. ^ http://www.tevapharm.com/news/teva_reports_full_year_2015_and_fourth_quarter_financial_results_02_16.aspx
  230. ^ "Teva Reports Fourth Quarter and Full Year 2014 Results". www.tevapharm.com.
  231. ^ http://www.tevapharm.com/news/teva_reports_fourth_quarter_and_full_year_2013_results_02_14.aspx
  232. ^ "Teva Reports Fourth Quarter and Full Year 2012 Results". tevapharm.com.
  233. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTI2NDkwfENoaWxkSUQ9LTF8VHlwZT0z&t=1
  234. ^ https://cdn0.scrvt.com/ec41840e14df52192984582863de63fa/da090e332ffb5df3/7b2f322f2d6e/Q3_FY2020_SHL_Quarterly-Statement.pdf
  235. ^ https://cdn0.scrvt.com/ec41840e14df52192984582863de63fa/c0b555cf8faef9d4/0e0d821eefe6/H1_FY2020_SHL_Half-year-financial-report.pdf
  236. ^ https://cdn0.scrvt.com/ec41840e14df52192984582863de63fa/1800000006835562/12e08501046c/Siemens-Healthineers-Annual-Report-2019.pdf
  237. ^ https://cdn0.scrvt.com/ec41840e14df52192984582863de63fa/1800000005904947/ef806566e5ee/Annual-Report-2018.pdf
  238. ^ https://cdn0.scrvt.com/ec41840e14df52192984582863de63fa/1800000004856382/73e26777cfa3/Siemens_Healthineers_Combined_Financial_Statements_FY17-15_V2_.pdf
  239. ^ https://cdn0.scrvt.com/ec41840e14df52192984582863de63fa/1800000004856382/73e26777cfa3/Siemens_Healthineers_Combined_Financial_Statements_FY17-15_V2_.pdf
  240. ^ https://cdn0.scrvt.com/ec41840e14df52192984582863de63fa/1800000004856382/73e26777cfa3/Siemens_Healthineers_Combined_Financial_Statements_FY17-15_V2_.pdf
  241. ^ https://www.biospace.com/article/releases/stryker-reports-second-quarter-2020-operating-results/?s=72
  242. ^ https://investors.stryker.com/press-releases/news-details/2020/Stryker-reports-2019-results-and-2020-outlook/default.aspx
  243. ^ a b https://s22.q4cdn.com/857738142/files/doc_financials/2018/Stryker_Annual_Report_2018.pdf
  244. ^ a b https://s22.q4cdn.com/857738142/files/doc_financials/2016/STRYKER-2016-AR.pdf
  245. ^ a b https://s22.q4cdn.com/857738142/files/doc_financials/2014/SYK_AR-14_4_29_15-FINAL.pdf
  246. ^ a b https://s22.q4cdn.com/857738142/files/doc_financials/2012/SYK-2012-AR_-03-14-13-FINAL_Single-Pages.pdf
  247. ^ https://investors.biogen.com/static-files/9d0b52a8-22b5-4742-af9d-8138469ac89f
  248. ^ https://investors.biogen.com/static-files/ce31eed8-8862-4bec-a63f-77c0fd6e15a1
  249. ^ http://investors.biogen.com/static-files/c0d4fbe2-d4f2-404b-be17-19e770386d6e
  250. ^ "Biogen's Spinraza: Great Launch, Rough Ride". 25 January 2018 – via www.bloomberg.com.
  251. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2016_on_Form_10K.pdf
  252. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2015_on_Form_10K.pdf
  253. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_2014_Annual_Report_Web.pdf
  254. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2013.pdf
  255. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2012.pdf
  256. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/2011ar.pdf
  257. ^ https://sw4503.swcms.net/en/ir-library/business-results/inframe/main/010/teaserItems1/00/linkList/0/link/4q2019_en_v1.pdf
  258. ^ "Astellas Pharma Inc. Annual Report 2018" (PDF). www.astellas.com.
  259. ^ https://www.biospace.com/article/releases/labcorp-announces-2020-second-quarter-results/?s=72
  260. ^ https://ir.labcorp.com/static-files/753d1464-9421-43f1-be83-d5e0be586800
  261. ^ a b c d e http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDE2OTE0fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636873221632383468
  262. ^ a b c http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjI4ODI1fENoaWxkSUQ9LTF8VHlwZT0z&t=1
  263. ^ https://www.biospace.com/article/releases/baxter-reports-second-quarter-2020-results/?s=72
  264. ^ http://d18rn0p25nwr6d.cloudfront.net/CIK-0000010456/c8c941c6-2b54-474e-9ffd-e4be95a75a58.pdf
  265. ^ a b https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2018/q4/Q4-2018-BAX-FINANCIAL-SCHEDULES-(FINAL).pdf
  266. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2017/q4/Q4-2017-BAX-FINANCIAL-SCHEDULES-(FINAL).pdf
  267. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2016/q4/Q4-2016-Financial-Schedules.pdf
  268. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2015/q4/Q4-2015-Financial-Schedules.pdf
  269. ^ https://s22.q4cdn.com/911189824/files/doc_financials/quarterly/2014/q4/Q4-2014-FINAL-Financial-Schedules.pdf
  270. ^ a b https://s22.q4cdn.com/911189824/files/doc_downloads/financial_schedules/2012/Reclassified-Sales-Final.pdf
  271. ^ https://s24.q4cdn.com/326377938/files/doc_financials/2020/q3/IQV-2020.09.30-10Q-FINAL_w-Exhibits.pdf
  272. ^ https://s24.q4cdn.com/326377938/files/doc_financials/2019/annual/IQV-2019-10-K-Filed-(with-exhibits).pdf
  273. ^ https://s24.q4cdn.com/326377938/files/doc_financials/2019/annual/IQV-2019-10-K-Filed-(with-exhibits).pdf
  274. ^ https://s24.q4cdn.com/326377938/files/doc_financials/2019/annual/IQV-2019-10-K-Filed-(with-exhibits).pdf
  275. ^ https://s24.q4cdn.com/326377938/files/doc_financials/annual/iqvia/QuintilesIMS_2016_Annual-Report_Final-(1).pdf
  276. ^ https://s24.q4cdn.com/326377938/files/doc_financials/annual/iqvia/QuintilesIMS_2016_Annual-Report_Final-(1).pdf
  277. ^ https://s24.q4cdn.com/326377938/files/doc_financials/annual/iqvia/QuintilesIMS_2016_Annual-Report_Final-(1).pdf
  278. ^ https://s24.q4cdn.com/326377938/files/doc_financials/annual/iqvia/QuintilesIMS_2016_Annual-Report_Final-(1).pdf
  279. ^ https://s24.q4cdn.com/326377938/files/doc_financials/annual/iqvia/QuintilesIMS_2016_Annual-Report_Final-(1).pdf
  280. ^ a b c d https://www.biospace.com/article/releases/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2019/?s=72
  281. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/2017-performance-report.pdf
  282. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BostonScientificFinalAR2016a.pdf
  283. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BostonScientificFinalComplete.pdf
  284. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/Boston-Scientific-2014-Annual-Report-and-10-K.PDF
  285. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BSXCombined-AR-and-10K.PDF
  286. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BSX-2012-AR-plus-10K.pdf
  287. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BSX-2011-AR.PDF
  288. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/2017-performance-report.pdf
  289. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BostonScientificFinalAR2016a.pdf
  290. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BostonScientificFinalComplete.pdf
  291. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/Boston-Scientific-2014-Annual-Report-and-10-K.PDF
  292. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BSXCombined-AR-and-10K.PDF
  293. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BSX-2012-AR-plus-10K.pdf
  294. ^ http://investors.bostonscientific.com/~/media/Files/B/Boston-Scientific-IR/annual-reports-proxy-statements/BSX-2011-AR.PDF

External links[edit]